Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Topoisomerase Inhibitor - 2019 Pipeline Insights & Growth Prospects Featuring GSK, Intezyme & RedxPharma - ResearchAndMarkets.com

November 8, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 8, 2019--

The “Topoisomerase Inhibitor -Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Topoisomerase Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Topoisomerase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Descriptive coverage of pipeline development activities for Topoisomerase Inhibitor

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Topoisomerase Inhibitor

The report assesses the active Topoisomerase Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the Report

Reasons to Buy

Companies Mentioned

Key Topics Covered

1. Report Introduction

2. Topoisomerase Inhibitor - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Topoisomerase Inhibitor Pipeline Products in Clinical Stages

6. Topoisomerase Inhibitor Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tct40s

View source version on businesswire.com:https://www.businesswire.com/news/home/20191108005199/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/08/2019 05:08 AM/DISC: 11/08/2019 05:08 AM